EC Number |
Activating Compound |
Reference |
---|
3.4.17.23 | 8-[[2-(dimethylamino)ethyl]amino]-5-(hydroxymethyl)-9-oxo-9H-xanthen-2-yl 4-methylbenzenesulfonate |
enhances ACE2 activity in a dose-dependent manner and causes considerable reductions in blood pressure and a striking reversal of cardiac and renal fibrosis in the spontaneously hypertensive rat model of hypertension |
692586 |
3.4.17.23 | all-trans retinoic acid |
- |
679704 |
3.4.17.23 | D-glucose |
incubation of cells in high D-glucose increases ACE2 activity |
732775 |
3.4.17.23 | losartan |
a specific angiotensin II receptor antagonist, is a well-known antihypertensive drug with a potential role in positively regulating ACE2 in the lung |
710616 |
3.4.17.23 | losartan |
an angiotensin II type 1 receptor blocker, increases central ACE2 activity. Losartan also restores brain ACE2 activity in transgenic RA mice, overview |
708683 |
3.4.17.23 | more |
ACE2 activity in plasma is not altered by ibuprofen treatment |
764930 |
3.4.17.23 | more |
ACE2 activity is not regulated by ibuprofen, flurbiprofen, etoricoxib or paracetamol |
764930 |
3.4.17.23 | more |
no activation by PD123319, an angiotensin II type 2 antagonist |
708683 |
3.4.17.23 | resorcinolnaphthalein |
enhances ACE2 activity in a dose-dependent manner |
692586 |
3.4.17.23 | SARS-CoV-2 |
ACE2 cleavage of des-Arg9-bradykinin substrate analogue is markedly accelerated by SARS-CoV-2 infection, while cleavage of angiotensin II analogue is minimally affected by the binding of spike protein |
763217 |